Review of the development of Chinese medicine in 2020

In recent years, with the advent of the aging era of the population and the general improvement of health awareness, disease prevention and early intervention into the background of the general trend, with the unique advantages of "cure the disease" of the Chinese medicine industry ushered in a good opportunity for development.
especially in the special circumstances of the 2020 new crown epidemic, Chinese medicine has played an important role, but also provided a good opportunity for its industrialization and development.
February 2020, the Central Committee to deal with the outbreak of new crown pneumonia leadership group meeting called for: strengthen the integration of Chinese and Western medicine, promote the depth of Chinese medicine involved in the whole process of diagnosis and treatment, timely promotion of effective prescriptions and traditional Chinese medicine.
, the State Administration of Traditional Chinese Medicine issued media reports, after screening research, jinhua clear particles, lotus clear plague capsules / particles and other Traditional Chinese medicine proved effective.
. Major Policy Review Following the Chinese Medicine Law, Healthy China "2030" and the Opinions on Promoting the Innovation and Development of Traditional Chinese Medicine, a series of policies have been issued at the national level to encourage support for the development of Chinese medicine.
28, 2019, the Basic Health Care and Health Promotion Law of the People's Republic of China was approved by a vote at the 15th session of the Standing Committee of the 13th National People's Congress and implemented on June 1, 2020.
The implementation of the Health China Strategy requires that "people's governments at all levels should give priority to the development of people's health", popularize healthy living, optimize health services, improve health security, build a healthy environment, develop healthy industries, improve the health of citizens throughout the life cycle, and give full play to the unique role of Chinese medicine in medical and health care and health undertakings.
In 2020, the State Administration of Market Supervision, the State Health And Health Commission and the State Administration of Traditional Chinese Medicine jointly strengthened the management of medical institutions, reformed the basic standards of pilot Chinese medicine clinics, strengthened the assumption of information-based standards for Chinese medicine and the construction of a talent pool;
The State Administration of Traditional Chinese Medicine and the State Drug Administration formulated the Principles for the Examination of Key Information of Ancient Classics, the Key Information Sheet of Ancient Classics (7 First Prescriptions) is the implementation of the policy of "Opinions on Promoting the Innovation and Development of Chinese Medicine Heritage" in 2019, and officially issued the Implementation Opinions on Promoting the Innovation and Development of Chinese Medicine Heritage, which provides a basis for the secondary development and innovation development of ancient classics.
standard-setting, regulate the industry for development.
In February 2020, the Guizhou Provincial Drug Administration approved Guizhou Yiyi Pharmaceutical Co., Ltd. as a pilot enterprise for the study of Chinese medicine formulation particles in Guizhou Province, and completed at least 400 kinds of Chinese medicine formula particle production process procedures, quality standards and other research work.
In December 2020, the Shanghai Drug Review and Verification Center of the Shanghai Drug Administration and the Shanghai Pharmaceutical Industry Association jointly drafted the General Specification for the Production of Chinese Medicine Formula Particles, which describes the general norms of the whole process of the production of Chinese medicine formula particles, covering the cultivation and cultivation of medicinal herbs, harvesting and initial processing of the origin, the preparation of Chinese medicine tablets, the production of Chinese medicine formula particles and other links.
provides a group standard with operaability for Chinese medicine formula particle production enterprises, which, while improving the production capacity of the industry, also greatly improves the regulatory efficiency of regulatory agencies and fills the gaps in the production and supervision of Chinese medicine formula particles in China.
Table 1:2020 Key Policies in the Field of Traditional Chinese Medicine Source: Firestone Creation according to public information finishing (the official website of the relevant departments) II, the development status of various sub-sectors From the industrial chain, the upper reaches of the Chinese medicine industry chain is the cultivation of Traditional Chinese medicine, medicinal resources related to downstream product quality, the strength of the industry leading enterprises have the whole industry chain development, master upstream valuable medicinal materials and other resources.
mid-tour is mainly Chinese medicine tablets and traditional Chinese medicine, of which chinese medicine drink tablets in the new drug formulation particles in recent years to maintain high-speed development.
mainly for Chinese medicine service institutions such as Chinese hospitals, Chinese medicine clinics and so on.
1. Upstream Chinese herbal medicine cultivation supply and quality is unstable, in recent years the growth rate of the industry has declined Chinese herbal medicine refers to unprocessed or not finished products, available for pharmaceutical raw materials, usually from natural plants, animals and minerals.
the efficacy of Chinese medicine products depends on the quality of Chinese herbal medicine, the stability and quality of the supply of Chinese herbal medicine directly affect the production and consumption terminal satisfaction of Chinese medicine products.
more than 90% of Chinese herbal medicines come from plants, and the cultivation area of Chinese herbal medicines has expanded further as local governments have promoted the implementation of the Implementation Plan for the Protection and Development of Chinese Herbal Medicines and the Action Plan for poverty alleviation in the Chinese herbal medicine industry (2017-2020).
data show that in 2019, China's medicinal cultivation area of about 2.6075 million hectares, mainly concentrated in Sichuan, Jilin, Liaoning, Hebei, Ningxia, Gansu, Hubei, Anhui, Hunan, Guangxi, Guangdong, Guizhou, Yunnan and other provinces and cities.
1: 2013-2020 China's cultivation of Chinese herbal medicine Source: National Bureau of Statistics, intellectual research consulting open information strength enterprise industrial chain extended upstream, the development of medicinal herbs cultivation.
In order to improve the voice and reduce the risk of upstream supply of Chinese herbal medicines, quality and price fluctuations, some powerful midstream enterprises in accordance with the suitable environment for the growth of Chinese herbal medicines, in a number of places to open up planting areas, take self-cultivation or in the base and farmers to expand the model of cooperative cultivation upstream, so as to strengthen the control of high-quality Chinese herbal medicines.
Such as Baiyunshan planted 30,000 mu of plate blue root in Fuyang, planted tens of thousands of mu of fields in Wenshan County, Yunnan Province, Tongrentang built 10,000 mu of Chinese herbal medicine base in Yutian, China Resources 39 has built wheat winter, appendix, red flower GAP planting base.
2. Mid-range Chinese medicine tablets, formula particles and traditional Chinese medicine (1) Chinese medicine tablets lack of technical specifications, standards vary, industry development fluctuations Chinese medicine tablets are a chinese medicine end products, is based on the theory of Traditional Chinese medicine, after selection, processing, preparation can be directly used in the clinical or preparation production of chinese medicine drugs, divided into traditional Chinese medicine tablets and new Chinese medicine tablets.
traditional Chinese medicine tablets are processed using modern concote methods.
New Chinese medicine drink tablets mainly refer to the extraction of the main ingredients through the modern preparation process, concentration and granulation of Chinese medicine tablets, such as Chinese medicine formula particles and Chinese medicine broken wall drink tablets.
The scale and industrialization of Chinese medicine beverage tablet processing enterprises is low, many small enterprises of Chinese medicine beverage tablets are farmers to take the model of family workshop-style factory to complete the processing of Chinese medicine tablets, drinking tablet factories only provide simple packaging services, the production process lack of technical specifications, coupled with weak industry supervision, so the standards of Chinese medicine beverage processing can not be unified, quality is uneven.
chinese medicine drink tablets policy control is strict, the industry's survival of the fittest intensified.
The Chinese government regulates Chinese medicine enterprises in accordance with the quality management norms for pharmaceutical production, and in 2019, a total of 114 pharmaceutical enterprises were withdrawn from their GMP certificates, involving 60 Chinese medicine tablet enterprises, accounting for 52.6% of the total, and the crude chinese medicine tablet enterprises were further eliminated.
the development of Chinese medicine tablets industry has fluctuated.
Chinese medicine tablets entered the list of base drugs in 2009 and achieved rapid development, strong momentum, sales revenue in 2017 reached 216.5 billion yuan, the bottom rebound in 2019, year-on-year growth rebounded to 12.7%.
Figure 2: 2015-2019 Sales revenue of Chinese medicine beverage tablet manufacturing industry Data sources: National Bureau of Statistics, Ministry of Industry and Information Technology (2) Chinese medicine formula particles pilot liberalization, the industry's high-speed development of Chinese medicine formula particles are Chinese medicine beverage tablets as raw materials, after water, separation, concentration, drying, granulation, packaging and other production processes, processed into a unified specification, unified dose, unified quality standards of the formula.
Its active ingredients, sexual taste, treatment, efficacy and traditional Chinese medicine tablets are completely consistent, maintaining the full characteristics of traditional Chinese medicine tablets, not only to ensure that traditional Chinese medicine dialectical treatment, flexible addition and subtract characteristics, better than traditional Chinese medicine, but also to avoid the trouble of the patient's traditional cooking, but also flexible single-taste particles, health and effective.
the national level has issued relevant incentives to explore a unified regulatory system and standards, in April 2001 "Provisional Provisions on the Management of Chinese Medicine Formula Particles" promulgated, after more than a decade has been approved enterprises to pilot the production of Chinese medicine formula particles.
Provincial pilot enterprises rapidly increased at present, only 6 enterprises (Jiangyin Tianjiang Pharmaceuticals, China Resources 39 Modern Chinese Medicine, Guangdong One Side Pharmaceutical Co., Ltd., Sichuan New Green Pharmaceuticals, Beijing Kangrentang Pharmaceuticals, Nanning Peili Pharmaceuticals) have obtained the national pilot qualifications, accounting for the vast majority of the market share.
Since the publication of the Measures for the Administration of Chinese Medicine Formula Particles (Draft for Comments) in 2015, Hebei, Zhejiang, Heilongjiang, Jilin, Anhui, Shaanxi, Henan, Shandong, Jiangxi, Guangdong and other provinces have issued documents to approve the pilot enterprises of Chinese medicine formula particles in various names, such as scientific research, pilot research, clinical pilot, technical reform, etc., and to carry out pilot and clinical use of Chinese medicine formula particles in the province.
2020, the Guizhou Provincial Drug Administration approved Guizhou Yiyi Pharmaceutical Co., Ltd. as a pilot enterprise for the study of Chinese medicine formulation particles in Guizhou Province.
incomplete statistics, the country has obtained various types of Chinese medicine formula particles pilot qualification of more than 60 enterprises.
The market for Chinese medicine formula particles is growing rapidly and is highly concentrated: according to the Blue Book of Research on the Development of Chinese Medicine Tablets Industry, the market size of Chinese medicine formula particles in China has increased from 2 billion yuan in 2010 to 15.1 billion yuan in 2018 with a compound annual growth rate of 33.48 percent.
released by the National Bureau of Statistics, the market size of Chinese medicine tablets in 2018 was about 171.5 billion yuan, with Chinese medicine formula particles accounting for about 8.8% of Chinese medicine tablets.
figure 3: In recent years, the market size of Chinese medicine formula particles and the proportion of Chinese medicine beverage tablets market data sources: "Chinese medicine beverage tablets industry development research blue book" Chinese traditional medicine is the leading enterprises in the Chinese medicine formula particle industry.
Of the six state-level pilot enterprises, Tianjiang Pharmaceuticals and One-Party Pharmaceuticals belong to Chinese traditional medicine enterprises, and among the provincial pilot enterprises, Chengtian Jinling Pharmaceuticals, Zhonglian Pharmaceuticals, Shuanglanxing Pharmaceuticals, Sanqiang Modern Chinese Medicine Division, Tianjiang Pharmaceuticals and other enterprises belong to the subsidiaries or holding shares of Chinese traditional medicine.
Red Day (Kang Rentang), New Green, China Resources 39 is firmly in the second camp, in the provincial pilot, Shenwei Pharmaceuticals enjoy Hebei's health insurance policy and rapid growth, Chinese medicine formula particles gradually become its core pillar.
Figure 4: Sales revenue of Chinese medicine formula particles in some enterprises (RMB 100 million) Data source: Enterprise announcement, Firestone Creation (3) Chinese traditional medicine enterprises strict control, in recent years sales decline policy, the development of slowing down in recent years.
In the past, Chinese medicine has benefited from the rapid development of medical insurance expansion, the production and sales revenue of Chinese medicine in 2015-2016 increased year by year, but in recent years has been hit by tender price reduction and sales, after 2017, Chinese medicine destocking, annual sales growth rate decreased, industry development slowed down.
Figure 5: Production of traditional Chinese medicine (tons) Data Source: wind, Firestone Creation Figure 6: Sales revenue of the manufacturing industry in China 2015-2019 (units: RMB100 million) Data source: National Bureau of Statistics, Ministry of Industry and Information Technology 3. End-use Chinese medicine service policy encouraged, steady growth of the industry According to 201 In the context of promoting the implementation of the filing system of Chinese medicine clinics, the number of Chinese medicine institutions increased significantly in 2019, bringing the total number of Chinese medicine medical and health institutions in 2019 to 65,809, an increase of 5,071 over 2018, and the expansion of the market demand for Traditional Chinese medicine and the outflow of prescriptions to promote the rapid development of Chinese medicine clinics.
By the end of 2019, China had 98.3% of community health service centers, 85.9% of community health service stations, 97.1% of township hospitals, 71.3% of village health rooms with the ability to provide Chinese medicine services, the total number of Chinese medicine and health personnel in China was 767,000, an increase of 7.27% over the previous year.
Figure 7: Number of Chinese medicine medical and health institutions in China, 2015-2019 Source: National Health and Health Commission, Department of Planning, Development and Information Technology, National Chinese Medicine Medical and Health Institutions, 2015-2019 The total number of visits increased from 910 million to 1.16 billion in 2019, with a compound annual growth rate of 4.97%, of which the largest increase was in 2019, at 8.4%.
from the distribution of the number of patients, mainly concentrated in Chinese medicine hospitals, accounting for 58%, Chinese medicine outpatient clinics and clinics accounted for 16.9%, medical institutions, Chinese medicine clinical departments accounted for 25.1%.
figure 8: Distribution of medical and health institutions in Chinese medicine in 2019 Data sources: National Health And Wellness Commission, Department of Planning, Development and Information Technology Private Chinese Medicine Museum is the mainstream trend of the development of Chinese medicine clinics, in addition to the comprehensive, specialized, clinic-type pharmacy and other mature models, Chinese medicine diagnosis and treatment "cure" to "cure the disease" extension, for the vast number of people in sub-health status to provide professional health management decisions, such as Chinese medicine health care hall, Chinese medicine physiotherapy hall, Chinese medicine, Chinese medicine beauty salon and other emerging "cure the disease" industry emerged.
In response to the Call of the Chinese Medicine Law on "Strengthening the Construction of the Chinese Medicine Talent Team", at the end of 2020, the State Administration of Traditional Chinese Medicine promulgated the "Publicity on the List of Chinese Medicine Innovation Teams and Talent Support Program Projects" and "Publicity on the List of Candidates for the Support Projects of Young Qi Huang Scholars", which opened the way for reforming chinese medicine talents, optimizing the growth path of talents and improving the incentive mechanism for talent evaluation mechanism.
, industry research and development investment and product acceptance, approval of the number of pieces of industry research and development investment ratio is low.
years, 72 listed enterprises in the whole Chinese medicine industry, the total research and development cost is only 8.163 billion yuan in 2018, research and development expenses accounted for 2.7% of revenue.
In
2019, there were only five Chinese medicine enterprises with more than 500 million research and development expenses, the number one enterprise Tiansli's research and development expenses were 810 million yuan, and the proportion of research and development expenses revenue was 4.26%, well below the 15.59% level of Hengrui Pharmaceuticals, a leading domestic company.
9: 2015-2020H3 Research and development costs of listed enterprises in the Chinese medicine industry and their revenue ratio Data sources: wind, firestone creation and finishing product innovation drug application registration number is small.
2016, the State Drug Administration has only approved the listing